RFI Partners With Ilhwa North America Ginseng Extract

RFI has entered into a manufacturing, formulation and sales partnership with Ilhwa NA Inc. (Pearl River, NY), a wholly-owned U.S. subsidiary of Korea’s groundbreaking ginseng company, Ilhwa Co Ltd.

7 Mar 2013 --- Ilhwa manufactures GS15-4, a high-absorption ginseng extract utilizing a patented high-yield, enzyme-fermented process. Winner of the BEST BOTANICAL 2012 award at Expo West/Engredea, this unique ginseng extract delivers ginseng with higher efficacy, more consistent absorption and an improved taste profile compared to conventional ginseng extracts.

GS15-4, “the 21st Century Ginseng Extract”, is a breakthrough technology (patents-pending) using enzyme fermentation to produce a completely balanced ginseng extract in its end-stage metabolite form. Human clinical studies have proven that it provides 15 times higher absorption, 4 times faster absorption and 4 times more consistent absorption. GS15-4 will transform how ginseng can be used in the natural ingredient market.

"Ilhwa is excited to establish this partnership with RFI,” said David C. Konn, president of Ilhwa North America. “RFI is a rare company that has created true vertical integration in the natural ingredient market. As the world leader in ginseng science, Ilhwa wanted to find the right partner to work with on this breakthrough in ginseng technology.”

“GS15-4 is a great fit with our current product line, especially our energy, stress and fermented product platforms,” said Jeff Wuagneux, president and CEO of RFI. “In addition, Ilhwa’s single passion for ginseng, its strong clinical science and its high quality manufacturing exemplify RFI’s From Field to Formula motto.”